TY - JOUR
T1 - (-)-Epigallocatechin gallate can prevent cisplatin-induced lung tumorigenesis in A/J mice
AU - Mimoto, Junko
AU - Kiura, Katsuyuki
AU - Matsuo, Keisuke
AU - Yoshino, Tadashi
AU - Takata, Ichiro
AU - Ueoka, Hiroshi
AU - Kataoka, Mikio
AU - Harada, Mine
PY - 2000
Y1 - 2000
N2 - Risks of secondary lung cancer in patients with non-small cell lung cancer and small cell lung cancer are estimated to be 1-2% and 2-10% per patient per year, respectively. Cisplatin is widely used in the treatment of lung cancer and is also known as a carcinogen in experimental animals. In this study, the effect of (-)-epigallocatechin gallate (EGCG) on cisplatin-induced lung tumors in A/J mice was investigated. Female A/J mice (4 weeks old) were divided into four groups: group 1, control without treatment; group 2, EGCG treatment (1 mg/ml in tap water); group 3, weekly cisplatin treatment (1.62 mg/kg body wt, i.p.) for 10 weeks; group 4, cisplatin plus EGCG treatment (EGCG was started 2 weeks before cisplatin treatment). Four groups of mice were killed at week 30 after treatment. Tumor incidence was 26.3% (5/19) in group 1, 30% (6/20) in group 2, 100% (19/19) in group 3 and 94.4% (17/18) in group 4. Tumor multiplicity (the number of tumors per mouse, mean ± SD) was 0.4 ± 0.8 in group 1, 0.4 ± 0.8 in group 2, 5.1 ± 2.1 in group 3 and 2.8 ± 2.3 in group 4. Tumor multiplicity was significantly reduced by adding EGCG to cisplatin-treated mice (P < 0.01). Furthermore, EGCG significantly reduced cisplatin-induced weight loss from 24.7-26.3% (cisplatin treatment) to 10.8-11.6% (cisplatin plus EGCG treatment) (P < 0.01). These findings suggest that EGCG can inhibit cisplatin-induced weight loss and lung tumorigenesis in A/J mice.
AB - Risks of secondary lung cancer in patients with non-small cell lung cancer and small cell lung cancer are estimated to be 1-2% and 2-10% per patient per year, respectively. Cisplatin is widely used in the treatment of lung cancer and is also known as a carcinogen in experimental animals. In this study, the effect of (-)-epigallocatechin gallate (EGCG) on cisplatin-induced lung tumors in A/J mice was investigated. Female A/J mice (4 weeks old) were divided into four groups: group 1, control without treatment; group 2, EGCG treatment (1 mg/ml in tap water); group 3, weekly cisplatin treatment (1.62 mg/kg body wt, i.p.) for 10 weeks; group 4, cisplatin plus EGCG treatment (EGCG was started 2 weeks before cisplatin treatment). Four groups of mice were killed at week 30 after treatment. Tumor incidence was 26.3% (5/19) in group 1, 30% (6/20) in group 2, 100% (19/19) in group 3 and 94.4% (17/18) in group 4. Tumor multiplicity (the number of tumors per mouse, mean ± SD) was 0.4 ± 0.8 in group 1, 0.4 ± 0.8 in group 2, 5.1 ± 2.1 in group 3 and 2.8 ± 2.3 in group 4. Tumor multiplicity was significantly reduced by adding EGCG to cisplatin-treated mice (P < 0.01). Furthermore, EGCG significantly reduced cisplatin-induced weight loss from 24.7-26.3% (cisplatin treatment) to 10.8-11.6% (cisplatin plus EGCG treatment) (P < 0.01). These findings suggest that EGCG can inhibit cisplatin-induced weight loss and lung tumorigenesis in A/J mice.
UR - http://www.scopus.com/inward/record.url?scp=0034019659&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034019659&partnerID=8YFLogxK
U2 - 10.1093/carcin/21.5.915
DO - 10.1093/carcin/21.5.915
M3 - Article
C2 - 10783312
AN - SCOPUS:0034019659
VL - 21
SP - 915
EP - 919
JO - Carcinogenesis
JF - Carcinogenesis
SN - 0143-3334
IS - 5
ER -